Anlotinib
- Generic Name
- Anlotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22FN3O3
- CAS Number
- 1058156-90-3
- Unique Ingredient Identifier
- GKF8S4C432
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Indication
用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。
用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Anlotinib in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02809534
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02752516
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 164
- Registration Number
- NCT02649361
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 113
- Registration Number
- NCT02586337
- Locations
- 🇨🇳
Jiangsu province tumor hospital, Nanjing, Jiangsu, China
🇨🇳Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT02586350
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Harbin medical university affiliated tumor hospital, Harbin, Heilongjiang, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 378
- Registration Number
- NCT02461407
- Locations
- 🇨🇳
The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China
🇨🇳The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳Fourth Hospital of Hebei Medical University Tumor Hospital of Hebei Province, Shijiazhuang, Hebei, China
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 233
- Registration Number
- NCT02449343
- Locations
- 🇨🇳
Gansu Cancer Hospital, Lanzhou, Gansu, China
🇨🇳Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Guangxi medical university affiliated tumor hospital, Nanning, Guangxi, China
Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 439
- Registration Number
- NCT02388919
- Locations
- 🇨🇳
Xinqiao Hospital, Chongqing, Chongqing, China
🇨🇳Gansu Provincial People 's Hospital, Lanzhou, Gansu, China
🇨🇳First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 419
- Registration Number
- NCT02332499
- Locations
- 🇨🇳
The 307th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳The 1st Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 133
- Registration Number
- NCT02072031
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Gansu Province Tumor Hospital, Lanzhou, Gansu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.